Review Article
A Review of NEPA, a Novel Fixed Antiemetic Combination with the Potential for Enhancing Guideline Adherence and Improving Control of Chemotherapy-Induced Nausea and Vomiting
Table 1
Key recommendations of antiemetic guideline groups.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
aNK1 RA (aprepitant) is given only if aprepitant was given on Day 1; if fosaprepitant was used then no follow-up NK1 RA is administered. bAC is classified as highly emetogenic. cPalonosetron is preferred 5-HT3. dGiven on Days 2–4 (i.e., an additional day). eIf olanzapine regimen was given on Day 1. fAs per highly emetogenic recommendations an NK1 regimen should be administered with certain MEC agents (e.g., carboplatin, doxorubicin, epirubicin, ifosfamide, irinotecan, and methotrexate). gIf olanzapine was given on Day 1. hOnly an option if a 5-HT3 other than PALO was used on Day 1. iSpecifically metoclopramide or prochlorperazine. AC: anthracycline cyclophosphamide; NK1 RA: neurokinin 1 receptor antagonist; 5-HT3 RA: serotonin receptor antagonist; DEX: dexamethasone; DRA: dopamine receptor antagonist; PALO: palonosetron. |